Navigation Links
Multiple Sclerosis Therapeutics Market to 2019 – Treatment Diversification and Pipeline Innovation to Drive Growth, Says a New Report at RnRMarketResearch.com
Date:9/8/2013

Dallas, Texas (PRWEB) September 08, 2013

The global multiple sclerosis therapeutics market has the potential to grow to a value of $17.9 billion by 2019. The market is currently led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake.

Scope of the report Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth (http://www.rnrmarketresearch.com/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-market-report.html) covers:

A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.

In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.

Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.

Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.

Discussion of the drivers and barriers for market growth or decay.

Deals and Strategic Consolidations covered in the report available for purchase at http://www.rnrmarketresearch.com/contacts/purchase?rname=113287 includes:

Major Co-development Deals
1 Daiichi Sankyo Enters into an Agreement with Amplimmune
2 Karo Bio Enters into an Agreement with Pfizer
3 Proteostasis Enters into an Agreement with Elan
4 Lycera Enters into an Agreement with Merck
5 Facet Enters into an Agreement with Trubion
6 UCB Enters into an Agreement with Biogen

Major Licensing Deals
1 Addex Extends its Licensing Agreement with Merck
2 Biogen Enters into a Licensing Agreement with Acorda Therapeutics
3 Genzyme Enters into a Licensing Agreement with Bayer Healthcare
4 Novartis Enters into a Licensing Agreement with Peptimmune
5 Merck Serono Enters into a Licensing Agreement with Apitope Technology
6 Antisense Enters into a Licensing Agreement with Teva Pharmaceutical
7 BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly
8 Biotica Enters into an Agreement with Wyeth

Complete report Multiple Sclerosis Therapeutics to 2019 – Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth is available at http://www.rnrmarketresearch.com/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-market-report.html .

Explore more reports on Multiple Sclerosis at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/multiple-sclerosis-drugs .

About Us:
RnRMarketResearch.com is an online market research reports (http://www.rnrmarketresearch.com/latest_reports) library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/multiple-sclerosis-ms/therapeutics-2019-market/prweb11097698.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: